A Phase 1, Single Center, Open-label Study of PF-07321332 Administrated as Multiple Oral Doses in Healthy Chinese Participants.
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 New trial record